Antiarrhythmic drug usage and prostate cancer: A population-based cohort study

Li Ting Kao, Chung Chien Huang, Herng Ching Lin, Chao Yuan Huang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Even though the relationship between antiarrhythmic drug usage and subsequent prostate cancer (PCa) risk has recently been highlighted, relevant findings in the previous literature are still inconsistent. In addition, very few studies have attempted to investigate the association between sodium channel blockers or potassium channel blockers for arrhythmia and the subsequent PCa risk. Therefore, this cohort study aimed to find the relationship between antiarrhythmic drug usage and the subsequent PCa risk using a population-based dataset. The data used in this study were derived from the Longitudinal Health Insurance Database 2005, Taiwan, China. We respectively identified 9988 sodium channel blocker users, 3663 potassium channel blocker users, 65 966 beta-blocker users, 23 366 calcium channel blockers users, and 7031 digoxin users as the study cohorts. The matched comparison cohorts (one comparison subject for each antiarrhythmic drug user) were selected from the same dataset. Each patient was tracked for a 5-year period to define those who were subsequently diagnosed with PCa. After adjusting for sociodemographic characteristics, comorbidities, and age, Cox proportional hazard regressions found that the hazard ratio (HR) of subsequent PCa for sodium channel blocker users was 1.12 (95% confidence interval [CI]: 0.84-1.50), for potassium channel blocker users was 0.89 (95% CI: 0.59-1.34), for beta-blocker users was 1.08 (95% CI: 0.96-1.22), for calcium channel blocker users was 1.14 (95% CI: 0.95-1.36), and for digoxin users was 0.89 (95% CI: 0.67-1.18), compared to their matched nonusers. We concluded that there were no statistical associations between different types of antiarrhythmic drug usage and subsequent PCa risk.

Original languageEnglish
Pages (from-to)37-42
Number of pages6
JournalAsian Journal of Andrology
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Anti-Arrhythmia Agents
Prostatic Neoplasms
Cohort Studies
Potassium Channel Blockers
Sodium Channel Blockers
Confidence Intervals
Population
Digoxin
Calcium Channel Blockers
Health Insurance
Drug Users
Taiwan
Comorbidity
Cardiac Arrhythmias
China
Databases

Keywords

  • antiarrhythmic drugs
  • cancer
  • digoxin
  • ion channel blocker
  • prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Antiarrhythmic drug usage and prostate cancer : A population-based cohort study. / Kao, Li Ting; Huang, Chung Chien; Lin, Herng Ching; Huang, Chao Yuan.

In: Asian Journal of Andrology, Vol. 20, No. 1, 01.01.2018, p. 37-42.

Research output: Contribution to journalArticle

@article{62bed2b9969648e2a930d7ffd2d94793,
title = "Antiarrhythmic drug usage and prostate cancer: A population-based cohort study",
abstract = "Even though the relationship between antiarrhythmic drug usage and subsequent prostate cancer (PCa) risk has recently been highlighted, relevant findings in the previous literature are still inconsistent. In addition, very few studies have attempted to investigate the association between sodium channel blockers or potassium channel blockers for arrhythmia and the subsequent PCa risk. Therefore, this cohort study aimed to find the relationship between antiarrhythmic drug usage and the subsequent PCa risk using a population-based dataset. The data used in this study were derived from the Longitudinal Health Insurance Database 2005, Taiwan, China. We respectively identified 9988 sodium channel blocker users, 3663 potassium channel blocker users, 65 966 beta-blocker users, 23 366 calcium channel blockers users, and 7031 digoxin users as the study cohorts. The matched comparison cohorts (one comparison subject for each antiarrhythmic drug user) were selected from the same dataset. Each patient was tracked for a 5-year period to define those who were subsequently diagnosed with PCa. After adjusting for sociodemographic characteristics, comorbidities, and age, Cox proportional hazard regressions found that the hazard ratio (HR) of subsequent PCa for sodium channel blocker users was 1.12 (95{\%} confidence interval [CI]: 0.84-1.50), for potassium channel blocker users was 0.89 (95{\%} CI: 0.59-1.34), for beta-blocker users was 1.08 (95{\%} CI: 0.96-1.22), for calcium channel blocker users was 1.14 (95{\%} CI: 0.95-1.36), and for digoxin users was 0.89 (95{\%} CI: 0.67-1.18), compared to their matched nonusers. We concluded that there were no statistical associations between different types of antiarrhythmic drug usage and subsequent PCa risk.",
keywords = "antiarrhythmic drugs, cancer, digoxin, ion channel blocker, prostate cancer",
author = "Kao, {Li Ting} and Huang, {Chung Chien} and Lin, {Herng Ching} and Huang, {Chao Yuan}",
year = "2018",
month = "1",
day = "1",
doi = "10.4103/aja.aja_26_17",
language = "English",
volume = "20",
pages = "37--42",
journal = "Asian Journal of Andrology",
issn = "1008-682X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Antiarrhythmic drug usage and prostate cancer

T2 - A population-based cohort study

AU - Kao, Li Ting

AU - Huang, Chung Chien

AU - Lin, Herng Ching

AU - Huang, Chao Yuan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Even though the relationship between antiarrhythmic drug usage and subsequent prostate cancer (PCa) risk has recently been highlighted, relevant findings in the previous literature are still inconsistent. In addition, very few studies have attempted to investigate the association between sodium channel blockers or potassium channel blockers for arrhythmia and the subsequent PCa risk. Therefore, this cohort study aimed to find the relationship between antiarrhythmic drug usage and the subsequent PCa risk using a population-based dataset. The data used in this study were derived from the Longitudinal Health Insurance Database 2005, Taiwan, China. We respectively identified 9988 sodium channel blocker users, 3663 potassium channel blocker users, 65 966 beta-blocker users, 23 366 calcium channel blockers users, and 7031 digoxin users as the study cohorts. The matched comparison cohorts (one comparison subject for each antiarrhythmic drug user) were selected from the same dataset. Each patient was tracked for a 5-year period to define those who were subsequently diagnosed with PCa. After adjusting for sociodemographic characteristics, comorbidities, and age, Cox proportional hazard regressions found that the hazard ratio (HR) of subsequent PCa for sodium channel blocker users was 1.12 (95% confidence interval [CI]: 0.84-1.50), for potassium channel blocker users was 0.89 (95% CI: 0.59-1.34), for beta-blocker users was 1.08 (95% CI: 0.96-1.22), for calcium channel blocker users was 1.14 (95% CI: 0.95-1.36), and for digoxin users was 0.89 (95% CI: 0.67-1.18), compared to their matched nonusers. We concluded that there were no statistical associations between different types of antiarrhythmic drug usage and subsequent PCa risk.

AB - Even though the relationship between antiarrhythmic drug usage and subsequent prostate cancer (PCa) risk has recently been highlighted, relevant findings in the previous literature are still inconsistent. In addition, very few studies have attempted to investigate the association between sodium channel blockers or potassium channel blockers for arrhythmia and the subsequent PCa risk. Therefore, this cohort study aimed to find the relationship between antiarrhythmic drug usage and the subsequent PCa risk using a population-based dataset. The data used in this study were derived from the Longitudinal Health Insurance Database 2005, Taiwan, China. We respectively identified 9988 sodium channel blocker users, 3663 potassium channel blocker users, 65 966 beta-blocker users, 23 366 calcium channel blockers users, and 7031 digoxin users as the study cohorts. The matched comparison cohorts (one comparison subject for each antiarrhythmic drug user) were selected from the same dataset. Each patient was tracked for a 5-year period to define those who were subsequently diagnosed with PCa. After adjusting for sociodemographic characteristics, comorbidities, and age, Cox proportional hazard regressions found that the hazard ratio (HR) of subsequent PCa for sodium channel blocker users was 1.12 (95% confidence interval [CI]: 0.84-1.50), for potassium channel blocker users was 0.89 (95% CI: 0.59-1.34), for beta-blocker users was 1.08 (95% CI: 0.96-1.22), for calcium channel blocker users was 1.14 (95% CI: 0.95-1.36), and for digoxin users was 0.89 (95% CI: 0.67-1.18), compared to their matched nonusers. We concluded that there were no statistical associations between different types of antiarrhythmic drug usage and subsequent PCa risk.

KW - antiarrhythmic drugs

KW - cancer

KW - digoxin

KW - ion channel blocker

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85040089041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040089041&partnerID=8YFLogxK

U2 - 10.4103/aja.aja_26_17

DO - 10.4103/aja.aja_26_17

M3 - Article

AN - SCOPUS:85040089041

VL - 20

SP - 37

EP - 42

JO - Asian Journal of Andrology

JF - Asian Journal of Andrology

SN - 1008-682X

IS - 1

ER -